Breast cancer
Conditions
Interventions
Sponsors
Jiangsu Cancer Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Female patients with metastatic breast cancer (MBC) admitted to our hospital from January 2021 to December 2023; 2. The patients aged between 18 and 70 years, and immunohistochemistry (3+) or fluorescence in situ hybridization (FISH, HER2/CEP17 ratio >= 2.0) are HER2 positive; 3. Hormone receptor status has been detected; 4. Left ventricular ejection fraction is more than 50%; 5. ECOG PS<=2; 6. The organ function of the enrolled patients is good; 7. Before enrollment, patients received endocrine therapy; 8. Patients may have received adjuvant chemotherapy or neoadjuvant chemotherapy, including or not including trastuzumab, before enrollment, with an interval of at least 6 months from the completion of adjuvant therapy or neoadjuvant therapy to the diagnosis of metastatic breast cancer; 9. Fully understand the study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Central nervous system transfer; 2. Prior exposure to a cumulative dose of doxorubicin exceeding 360 mg/m^2 or equivalent; 3. Other investigators judged that it did not conform to the situation of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall response rate at 24 weeks; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate;Duration of remission;Progression free survival; | — |
Countries
China
Contacts
Public ContactHe Xia
Jiangsu Cancer Hospital
Outcome results
None listed